WHO’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) today finalized a licensing agreement with the Spanish National Research Council (CSIC) for a COVID-19 serological antibody technology. The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to a COVID-19 infection or to a vaccine. This represents the first transparent, global, non-exclusive licence for a COVID-19 health tool, and the first test licence signed by MPP and included in the WHO Pool.
Sales of the test for use in LMICs will be on a royalty-free basis and the MPP are now seeking manufacturers willing to take up the technology, especially those based in LMICs. See more on the press release below and spread the word if you know any companies interested in antibody testing/ELISAs for SARS-CoV-2!
The license agreement itself is linked on this page: